Cumberland Pharmaceuticals Inc.
NASDAQ:CPIXDrug Manufacturers - Specialty & Generic
-$0.06 today
- Market cap
- $98.52M
- Beta
- 0.10
- P/E (TTM)
- -11.5
- EPS (TTM)
- -$0.48
Volume 0.16M
Average 0.97M
CPIX Deferred Tax Liabilities
Taxes owed in future periods because of timing differences between accounting and tax rules.
Cumberland Pharmaceuticals Inc.NASDAQ: CPIX
Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026
Deferred tax liabilities remains negative
Q1 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier.
Context
- Deferred tax liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Deferred tax liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Tax Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Tax Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Tax Liabilities vs competitors
How CPIX compares with its peers on the latest reported figures
- CPIX's Mar 2026 deferred tax liabilities of $0 is the 2nd highest of the 4 companies compared; the peer median is $0.
- Deferred tax liabilities amounts to 0.0% of total assets for CPIX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $12K | +33.3% | +10.1% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CPIX) | $0 | +33.3% | +10.1% | 0.0% | |
Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 27.04M | 19.76M | 18.32M | 17.96M | 11.44M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 6.88M | 13.16M | 9.76M | 11.7M | 16.94M |
| Inventory | 8.43M | 9.86M | 4.61M | 4M | 6.23M |
| Other Current Assets | 0 | 3.08M | 3.03M | 2.79M | 2.45M |
| Total Current Assets | 45.69M | 45.87M | 35.71M | 36.45M | 37.06M |
| Property, Plant & Equipment (Net) | 1.47M | 5.5M | 7.04M | 6.45M | 8.61M |
| Goodwill | 882K | 914K | 914K | 914K | 914K |
| Intangible Assets | 23.95M | 30.59M | 22.61M | 17.97M | 14.03M |
| Long-term Investments | 0 | 0 | 0 | 0 | 3.99M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.47M | 10.05M | 15.5M | 13.79M | 12.23M |
| Total Non-current Assets | 38.77M | 47.05M | 46.06M | 39.13M | 39.76M |
| Total Assets | 84.46M | 92.93M | 81.78M | 75.58M | 76.82M |
| Account Payables | 9.64M | 10.82M | 14.04M | 13.91M | 18.57M |
| Short-term Debt | 0 | 0 | 0 | 5.1M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.96M | 13.57M | 10.79M | 10.18M | 14.92M |
| Total Current Liabilities | 19.28M | 28.58M | 27.98M | 31.62M | 36.74M |
| Long-term Debt | 15M | 16.2M | 12.78M | 10.18M | 5.24M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 7.49M | 7.59M | 6.45M | 6.3M | 5.82M |
| Total Non-current Liabilities | 22.58M | 28.37M | 24.53M | 21.42M | 15.53M |
| Total Liabilities | 41.86M | 56.95M | 52.52M | 53.04M | 52.28M |
| Common Stock | 48.45M | 47.47M | 47.09M | 46.82M | 51.68M |
| Retained Earnings | (5.64M) | (11.21M) | (17.49M) | (23.97M) | (26.8M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (212.33K) | (292.13K) | (343.57K) | (307.52K) | (336.1K) |
| Total Equity | 42.6M | 35.97M | 29.26M | 22.55M | 24.54M |
| Total Debt | 16.06M | 20.96M | 18.43M | 20.57M | 10.18M |
| Net Debt | (10.98M) | 1.2M | 106.86K | 2.61M | (1.26M) |
Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.